Valore20202021202220232024TTMSpese di vendita, generali e amministrative747 M818 M828 M926 M1.1 B—Ricerca e sviluppo226 M230 M236 M274 M320 M—Reddito operativo332 M389 M695 M813 M842 M—Proventi non operativi, Totale——————Oneri finanziari, al netto degli interessi capitalizzati——————Proventi non operativi, esclusi gli oneri finanziari——————Entrate/uscite straordinarie——————Utile al lordo delle imposte361 M426 M734 M862 M900 M—Quota di utile——————Imposte125 M115 M186 M194 M229 M—Interessi di minoranza————8 M—Altri proventi/oneri al netto delle imposte——————Utile netto al lordo delle attività cessate236 M311 M548 M668 M671 M—Attività cessate——————Utile netto236 M311 M548 M668 M671 M—Regolazione della diluizione——————Dividendi privilegiati——————Utile netto diluito attribuibile agli azionisti ordinari——————Utile base per azione (EPS base)——————Utile diluito per azione (EPS diluito)——————Numero medio di azioni ordinarie in circolazione——————Azioni diluite in circolazione——————EBITDA——————EBIT1.52 B1.71 B1.99 B2.2 B2.42 B—Costo del fatturato1.19 B1.32 B1.3 B1.39 B1.58 B—Altri costi del venduto——————Ammortamento e svalutazione (liquidità)——————
Dr. Reddy's Laboratories Ltd
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr.